INJ just received another big piece of news! 21Shares updates its ETF filing, making institutional capital entry increasingly clear
On September 19, 21Shares submitted a revised S-1/A filing for the Injective ETF to the U.S. SEC, effectively updating the earlier application.
If approved later, the ETF plans to list on Nasdaq under the ticker TINJ, passively tracking INJ’s price performance via the FTSE Injective Index. It also plans, depending on the situation, to pledge a portion of its holdings to seek additional returns.
In simple terms, before this, retail investors who wanted to access INJ mainly did so through spot or similar approaches; if the ETF is ultimately approved, traditional financial markets would gain another compliant channel to access INJ.
Moreover, 21Shares has already launched an Injective staking ETP in Europe, and this time it is pushing further into the U.S. market—indicating that institutions’ plans for INJ-related products are continuing.
That said, note that this is only an application update and does not mean the ETF has been approved yet. Whether it can ultimately be rolled out still depends on regulatory progress. For INJ, ETF expectations and the inflow of capital are worth watching, but for the short term, market action will still depend on how real capital reacts.$AVA $BTW $COTI
On September 19, 21Shares submitted a revised S-1/A filing for the Injective ETF to the U.S. SEC, effectively updating the earlier application.
If approved later, the ETF plans to list on Nasdaq under the ticker TINJ, passively tracking INJ’s price performance via the FTSE Injective Index. It also plans, depending on the situation, to pledge a portion of its holdings to seek additional returns.
In simple terms, before this, retail investors who wanted to access INJ mainly did so through spot or similar approaches; if the ETF is ultimately approved, traditional financial markets would gain another compliant channel to access INJ.
Moreover, 21Shares has already launched an Injective staking ETP in Europe, and this time it is pushing further into the U.S. market—indicating that institutions’ plans for INJ-related products are continuing.
That said, note that this is only an application update and does not mean the ETF has been approved yet. Whether it can ultimately be rolled out still depends on regulatory progress. For INJ, ETF expectations and the inflow of capital are worth watching, but for the short term, market action will still depend on how real capital reacts.$AVA $BTW $COTI
